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In this review, we will discuss the enzymes that are involved in the synthesis and degradation of
glycoconjugates and we will give an overview of the inhibitors and activity-based probes (ABPs) that
have been used to study these. Following discussion of some general aspects of the biosynthesis and
degradation of N-linked glycoproteins, attention is focused on the enzymes that hydrolyze the
protein–carbohydrate linkage, peptide N-glycanase and glycosylasparaginase and their mechanism. We
then focus on the biosynthesis of O-linked glycoproteins and glycolipids and in particular on the
enzymes that hydrolyze the interglycosidic linkages in these, the glycosidases. Some important
mechanism-based glycosidase inhibitors that form a covalent bond with the targeted enzyme(s), their
corresponding ABPs and their application to study this class of enzymes are highlighted. Finally,
alternative pathways for degradation of glycoconjugates and an ABP-based strategy to study these will
be discussed.
Glycoconjugates are a highly diverse class of biomolecules that
partake in many biological processes.1 Glycoconjugates can be
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divided into three major types, namely N-linked glycoproteins,
O-linked glycoproteins and glycolipids. The b-glycosyl–asparagine
amide bond, formed by post-translational modiﬁcation of the side
chain of asparagine, is the major type of glycosidic linkage in N-
linked glycoproteins.2 The linkages found in O-glycoproteins and
glycolipids are much more diverse, and threonine, serine, tyrosine,
hydroxylysine and hydroxyproline are subject to modiﬁcation
with monosaccharides or oligosaccharides of various natures.3
Glycolipids in turn differ in both the lipid part (for instance
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cholesterol, ceramide) and the nature of the (oligo)saccharide
fragment. Aberrations in either the nature of glycoconjugates
or their metabolism are at the basis of a variety of diseases,
and thus insight in glycoconjugate processing and functioning
is of utmost importance in understanding and combating these
diseases. For instance, altered glycoconjugate patterns are often
found on human tumors and provide an entry for anti-tumor
drug development.4 Aberrations in glycolipid metabolism or the
degradation of N-glycosylated proteins are at the basis of a
wide number of human genetic disorders called lysosomal storage
disorders.5
In the study of glycoconjugate processing enzymes in biological
samples, mechanism-based inhibitors and activity-based probes
(ABPs) are increasingly applied as research tools. In this review,
we will discuss the enzymes that are involved in the synthesis
and degradation of glycoconjugates and we will give an overview
of the inhibitors and ABPs that have been used to study these.
Following a short introduction on the concept of activity-based
protein proﬁling some general aspects on the biosynthesis and
degradation of N-linked glycoproteins are discussed. Attention is
focused on the enzymes that hydrolyze the protein–carbohydrate
linkage, peptide N-glycanase and glycosylasparaginase and their
mechanism. The next part of this review focuses on the biosynthe-
sis of O-linked glycoproteins and glycolipids and in particular on
the enzymes that hydrolyze the interglycosidic linkages in these,
the glycosidases. Some important mechanism-based glycosidase
inhibitors that form a covalent bond with the targeted enzyme(s),
their corresponding ABPs and their application to study this
class of enzymes are highlighted. Finally, alternative pathways
for degradation of glycoconjugates and ABP-based strategies to
study these will be discussed.
Activity-based protein proﬁling
In activity-based protein proﬁling (ABPP), activity-based probes
(ABPs) are employed to speciﬁcally modify an enzyme or a class
of enzymes in a complex sample (cell extract, living cells or animal
models). In the next step, the tagged enzymes are identiﬁed and/or
analyzed by ﬂuorescence read out or mass spectrometry-based
proteomics techniques (Fig. 1A).6 An ABP generally consists of
three structural elements, being a reactive group (also knownas the
warhead), a linker anda tag/ligationhandle, or label (Fig. 1B). The
warhead covalently attaches the probe to the enzyme (or enzyme
family) of interest and should only react with active enzymes;
hence the name activity-based probe. The design of a reactive
group is thus guided by the mechanism of the enzyme. Often an
electrophilic group is used as a warhead, which selectively reacts
with the nucleophilic residue in the active site. The linker connects
the warhead to the label and thereby introduces additional spacing
between both functional groups. This spacing minimizes the steric
hindrance between the reporter group and active site of the enzyme
in order to disturb as little as possible the binding of the probe.
Additionally, the linker moiety of the probe can be adapted to
provide selectivity for the enzyme (or enzymes) of interest, to
increase the hydrophilicity of the ABP and for quantiﬁcation
of the labeled proteins by mass spectrometry. For example,
introduction of structural elements in the linker part, such as
peptides, resulted in speciﬁc protease probes.7 PEG-spacers have
been used to increase the solubility of ABPs. For quantiﬁcation
purposes, isotope coded linkers may be incorporated in ABPs.8
Such probes contain either H/D or 12C/13C and share almost
the same physical and chemical properties. After labeling and
digestion of two different protein samples, the labeled peptides
will therefore co-elute in LCMS experiments. By comparing the
relative signals of these peptides, the relative abundance of the
protein in the two different samples can be determined. The
tag is used to visualize and/or purify the labeled enzymes. Both
afﬁnity tags, such as biotin, and ﬂuorophores, such as a BODIPY,9
a ﬂuorescein or a rhodamine moiety, are frequently applied in
activity-based proteomics. Incorporation of a ﬂuorophore tag is
an attractive strategy to allow rapid in-gel detection of labeled
proteins (Fig. 1A, path i). Furthermore, such ABPs can be used
to study enzymes in living cells by means of ﬂuorescence imaging
microscopy and ﬂuorescence activated cell sorting. Biotin is often
used to enrich labeled proteins by means of streptavidin pull-
down after which the enriched proteins are identiﬁed by mass
spectrometry (Fig. 1A, path ii).10 Alternatively, the biotin moiety
allows in-gel detection by streptavidin-horseradish peroxidase
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Fig. 1 (A) In a typical ABP labeling experiment, a proteome is treated with an activity-based probe. The labeled enzymes are either directly visualized
with SDS-PAGE followed by ﬂuorescent imaging (i) or are puriﬁed by streptavidin pull-down, digested with trypsin after which the peptides are analyzed
by mass spectrometry (ii). In a two-step labeling experiment, a bioorthogonal ligation is performed after treating the proteome with the ABP. (B)
Schematic representation of an ABP. (C) Bioorthogonal reactions used to modify azide containing ABPs. Top: Staudinger–Bertozzi ligation, middle:
copper-catalyzed click reaction, bottom: strain-promoted click reaction.
Fig. 2 The synthesis of glycoproteins.
blotting. On the downside of the ABPs described so far, the
inherent steric bulk of a tag (biotin/ﬂuorophore) may obstruct
binding of the ABP to the targeted enzyme(s). Next to this the
tag, especially biotin, may have a detrimental effect on the cell-
permeability of the probe. Obviously, biotin or ﬂuorescent tags
are normally not part of the natural substrate of the targeted
enzyme(s), and ABPs equipped with these may be structurally
rather removed from the actual enzyme substrates. This poses some
difﬁculties on the translation of data on enzyme–ABP binding to
substrate preferences as exerted by the enzyme or enzymes at hand.
With the speciﬁc aim to overcome these caveats, two-step labeling
strategies have come to the fore in recent years. In these strategies,
the tag in an ABP is replaced by a small bioorthogonal ligation
handle, most commonly an azide or alkyne. After labeling, these
ligation handles can be conjugated to the tag using the Staudinger–
Bertozzi ligation, the copper-catalyzed click reaction or the strain
promoted click reaction (Fig. 1C).11 The implementation of ABP
tools has met with considerable success in the areas of esterases
and proteases, both in the study of known entities in physiological
processes and in unearthing new hydrolytic activities belonging
to these classes. Recent years have witnessed the ﬁrst successful
development ofABP tools and techniques aimed at enzyme classes
other than esterases/proteases, in particular also the subject of this
review, glycosidase activities.
The biosynthesis of N-linked glycoproteins
In eukaryotes, the majority of N-linked glycoproteins are syn-
thesized by membrane-bound ribosomes on the endoplasmic
reticulum (ER) (Fig. 2). The newly synthesized proteins are
inserted into the ER lumen via a specialized structure referred
to as the translocon.12 In a co-translational process, oligosac-
charyl transferase may glycosylate asparagine residues within
the Asn–Xxx–Ser/Thr (Xxx = any amino acid excepting Pro)
consensus sequence forming an N-linked glycan.13 Glycosylation
of the growing peptide chain increases the hydrophilicity of
the unfolded peptide and thereby prevents its aggregation. The
outermost glucose residue of the Glc3Man9GlcNAc2 N-linked
oligosaccharide is rapidly removed by glucosidase I, which is
followed by hydrolysis of the second glucose residue by glucosidase




























































II. The chaperones calnexin and calreticulin bind to the formed
GlcMan9GlcNAc2 and aid in folding of the peptide chain.14
Protein disulﬁde isomerase binds to these chaperones and catalyzes
the formation of disulﬁde bonds.15 Upon release of the protein
from calnexin and calreticulin, glucosidase II cleaves the inner
most glucose. In mammalian cells, the folding state of the protein
is monitored by UDP-glucose:glycoprotein glucosyltransferase
(UGGT), which recognizes hydrophobic patches.16 Misfolded
proteins are re-glucosylated and subsequently re-enter the cal-
nexin/calreticulin cycle. Properly folded proteins progress through
theERandGolgi.A series of deglycosylation/glycosylation events
transform the high mannose N-glycans into complex-type N-
glycans. These glycans in turn help in guiding the glycoprotein
to its ﬁnal destination, such as the cell surface or the endocytic
pathway. There are two main degradation pathways for N-linked
glycoproteins. The folding state and location of the glycoprotein
determines the pathwaybywhich it is degraded.Newly synthesized
N-glycoproteins that are persistently misfolded in the ER are
degraded by the endoplasmic reticulum associated degradation
pathway (ERAD). Mature proteins are, after performing their
function, ﬁnally degraded in the lysosome.
Endoplasmic reticulum associated degradation pathway
Up to 10% of the newly synthesized glycoproteins in the ER are
persistentlymisfolded and are destined for degradation.17 Depend-
ing on region that is misfolded, the proteins will be recognized
and extracted by a different subset of proteins. For glycoproteins,
it was shown that the N-glycans play an important role in this
ingenious process. In contrast to normally folded glycoproteins,
theN-glycans on misfolded proteins are extensively trimmed (Fig.
3) in the ER and it was therefore long thought that the N-glycans
acted as a folding timer. Hydrolysis of the a-1-2 linked mannose
of branch A blocks reglucosylation of the glycan by UGGT18
and thereby prevents futile folding attempts. Furthermore, the
a-1-6 linked mannose residue formed upon trimming of branch
C either in combination with trimming of the branch B19 or
as sole modiﬁcation20 serves as a signal for degradation. The
enzyme that removes the mannose residue of branch B was
identiﬁed as ER a-mannosidase I.21 Which mannosidases are
involved in the trimming of the branches A and C is still a
matter of debate. The ER degradation enhancing a-mannosidase
I like proteins 1–3 (EDEMs 1–3) have been suggested as potential
candidates. Despite their resemblance with ER a-mannosidase I,
it was originally thought that the EDEMs act as lectins which
speciﬁcally recognize trimmed N-glycans.22 Olivari et al. however
showed that overexpression of EDEM1 resulted in the removal
of the a-1,2-linked mannose residue of branch A in vivo thereby
accelerating degradation of the glycoproteins18 and similar results
were obtained for overexpression Htm1p, the yeast homologue
of EDEMs.19 Additionally, overexpression of EDEM3 leads to
the formation of Man7GlcNAc2 and Man6GlcNAc2 in vivo.23 The
inﬂuence of EDEM1 and EDEM3 on trimming was abolished by
mutating the putative catalytic residues. This data points to the
EDEMs as being active mannosidases. However data of another
study using human EDEM1 suggest that instead of being a
mannosidase, EDEM1 downregulates the proteolytic degradation
of ER a-mannosidase I and that the resulting increased levels
of ER a-mannosidase I account for the extensive trimming of
N-glycans.24 The lectin, human OS-9, speciﬁcally binds to the
a 1–6 linked mannose residue of branch C of the trimmed
glycan.25 This lectin forms a large protein complex that includes
an ubiquitin ligase.26 This complex is thought to be responsible for
ubiquitination and retrotranslocation of the glycoproteins to the
cytosol. Inside the cytosol, the glycoproteins are deglycosylated
by cleavage of the b-aspartyl-glucosamine bond by cytoplasmic
peptide N-glycanase (PNGase) and degraded by the proteasome
and aminopeptidases.
PNGase belongs to the transglutaminase family and was ﬁrst
detected in yeast.27 After identiﬁcation of the gene encoding
PNGase in yeast, the function and structure of this enzyme has
received a lot of attention.28 X-ray crystallography showed that
the catalytic residue of PNGase is located in the middle of a
long deep cleft (8 A˚ wide and 30 A˚ long).29 The carbohydrate
part of a glycoprotein binds to one end of the cleft and the
peptide part binds at the other side of it. To bind efﬁciently
to PNGase, the folding state of the substrate is of importance
as was demonstrated in 2004 by Hirsch et al. in an activity-
based assay. They found that RNAse B has to be denatured to
enable deglycosylation by PNGase.30 Computer models of native
glycosylated proteins bound to the Ro¨ntgen diffraction structure
of PNGase illustrate why proteins need to be unfolded before
they can bind to PNGase. The walls of the deep cleft in which
the active site is located obstruct binding of native N-linked
glycoproteins. The globular structure of unfolded proteins, on the
other hand, does ﬁt with the requirements of the active site and
can therefore bind to PNGase. Upon binding of the substrate, the
carbohydrate-protein linkage is hydrolyzed as depicted in Fig. 4.
Cysteine 191 of the catalytic Cys, His, Asp triad, characteristic
for many cysteine proteases/transglutaminases, attacks the amide
bond forming tetrahedral adduct 1. Thio-ester 2 is formed upon
collapse of oxyanion 1 and the oligosaccharide is liberated.
Subsequently, thio-ester 2 is hydrolyzed, regenerating the active
enzyme. The Ro¨ntgen diffraction structure of yeast PNGase
Fig. 3 Schematic representation of ERAD.




























































Fig. 4 Mechanism of peptide N-glycanase.
furthermore reveals that the N-terminal and C-terminal parts
of the yeast protein form a hydrophobic patch which interacts
with the ubiquitin receptor Rad23, coupling yeast PNGase to the
proteasomal pathway.31 In higher organisms, PNGase contains an
N-terminal putative protein–protein interaction domain (PUB-
domain).32 Next to Rad23 homologues, various other proteins
have been reported to forma complexwith these patches, including
the ATPase Associated with diverse cellular Activities which is
possibly involved in the extraction of misfolded proteins from the
ER and ubiquitin ligases which are responsible for ubiquitination
of misfolded proteins
PNGase inhibitors and activity-based probes
Broad-spectrum caspase inhibitor Z-VAD-Fmk 3 (Fig. 5) was the
ﬁrst inhibitor reported for PNGase and was discovered by library
screening.33 Misaghi et al. revealed that this peptidyl ﬂuoromethyl
ketone covalently and irreversiblymodiﬁedPNGase, as the activity
of PNGase inhibited with 3 could not be restored by dialysis. To
study the site of binding of Z-VAD-Fmk 3, an active site mutant
with the nucleophilic cysteine mutated to an alanine residue was
used. According to MALDI-MS, enzymes lacking this active
site cysteine residue were, in contrast to wild-type enzyme, not
labeled by Z-VAD-Fmk. These results indicate that the inhibition
of PNGase is caused by the selective modiﬁcation of the thiol
of cysteine 191. Later, the binding-site of 3 was validated by the
X-ray structure of 3with PNGase.25 To determinewhich structural
parts of the inhibitor are important for binding, Misaghi et al.
synthesized diastereomerically pure Z-VAD-Fmk 3a and 3b and
Z-VAD-Fmk analogues 4–6. The stereochemistry of the aspartic
acid residue in Z-VAD-Fmk (commercial available Z-VAD-Fmk is
a diastereomeric mixture) proved not important for binding, and
both isomers 3a and 3b inhibit the enzyme with equal efﬁciency.
The position of the electrophilic trap and the aspartyl side chain
at position 1 however plays a key role in inhibition of PNGase.
Analogues bearing a ﬂuoromethyl ketone on their side chain (4 and
5) did not inhibit the enzyme. Compounds lacking the carbonyl
at their side chain such as Z-VAA-Fmk 6 or compounds in which
the aspartyl side chain is replaced by a glutamyl side chain such
as Z-VAE(OMe)-Fmk 7 were also inactive. A main and obvious
disadvantage of Z-VAD-Fmk as PNGase inhibitor is its intrinsic
reactivity towards caspases.
In the search for selective inhibitors, attention has been focused
on the design of PNGase inhibitors based on the carbohydrate
part of N-glycoproteins. Initially, Ito and co-workers designed
a set of ﬁve inhibitors (8–12, Fig. 6).34 The high-mannose-type
oligosaccharides 8 and 9 equipped with an iodoacetamide trap are
mimics of the highmannoseN-glycans of the natural substrate. In-
hibitors 10–12 contain the core chitobiose as recognition element.
In a substrate-based assay, it appeared that oligosaccharides 8
and 9 are very potent inhibitors of PNGase (IC50 ~1.6 mM). To
evaluate whether 8 and 9 covalently modiﬁed PNGase, Ito and co-
workers performed a labeling experiment. SDS-PAGE revealed a
distinct shift in molecular weight of PNGase treated with 8 and
9. Furthermore, they could visualize the glycosyl–PNGase adduct
using lectin blotting. Labeling proved to be very selective and
caspases 2, 3 and 7 and bovine serum albumin were not modiﬁed
with 8 and 9. Also in E. coli extracts, exclusive labeling of PNGase
was observed.Mass spectrometry analysis clearly revealed Cys191
of the catalytic triad as the target of the inhibitors. Interestingly,
truncated analogues such as disaccharides 10, 11 and 12 also inac-
tivated PNGase efﬁciently (IC50 4, 0.1 and 0.1 mM), despite their
reduced binding afﬁnity. Shortly after these studies, we published
two new chitobiose-based inhibitors of PNGase, 13 and 14.35 Of
these, epoxysuccinate 13 is a potent inhibitor of PNGase and the
potency of this compound is comparable to chloroacetamide 10.
Fluoromethylketone 14 however proved to be a poor inhibitor of
PNGase that blocks activity at high micromolar concentrations.
These results prompted the study towards structural requirements
essential for binding to PNGase. To establish the inﬂuence of
the reactive group on the binding afﬁnity, we synthesized a
set of ﬁfteen chitobiose-based inhibitors containing a variety of
warheads, including methylketones/acetamides equipped with a
leaving group, epoxides, aziridines and Michael acceptors (15–29,
Fig. 6).36 After biological evaluation of this set of inhibitors, it
Fig. 5 Peptide based inhibitors of PNGase.




























































Fig. 6 A) High mannose based inhibitors of PNGase. (B) Chitobiose-based inhibitors. (C) Monosaccharide and cellobiose based inhibitors.
became evident that the nature of the warhead is crucial for the
potency of the inhibitor. In general, three trends can be observed.
(1) Acetamides/methylketones inhibitors bearing a good leaving
group (17 and 20) are superior to inhibitors containing a poor
leaving group (15, 16, 18, 19, 21 and 22). (2) The potency of
S,S-conﬁgured epoxysuccinate/aziridine dicarboxylate warhead
containing compounds such as 13 and 26 is comparable to that of
chloroacetamides/chloromethylketones and these compounds are
approximately 100-fold more active then compounds containing
the corresponding R,R-conﬁgured warheads (23 and 27). Fur-
thermore, acylation of the aziridine warhead is a prerequisite.
(3) Finally Michael acceptors, such as vinyl sulfone 28 and vinyl
ester 29 appeared to be poor inhibitors of PNGase. Next to the
nature of the warhead also the location thereof plays a vital role as
was shown by Ito and co-workers.37 In contrast to good inhibitor
10, chloropropionamide 30 in which the leaving group is shifted
one carbon atom do not inhibit PNGase. In the same paper,
Ito and co-workers investigated the inﬂuence of the carbohydrate
part on binding with monosaccharide inhibitors (31–34, Fig. 6)
and cellobiose inhibitor 35. At least two glucosamine residues
are required for binding, since monosaccharides 31–34 do not
inhibit the enzyme, this in contrast to chitobiose inhibitors 10–
12 and 14. Furthermore, the importance of the N-acetyl group
was demonstrated. Compounds lacking the N-acetyl, such as
disaccharide 35, are poor inhibitors.
The peptide and carbohydrate-based inhibitors described above
have been used as lead for the design of two ABPs for PN-
Gase. ABP 36 was obtained by replacing the benzyloxycarbonyl
group in broad-spectrum caspase inhibitor Z-VAD-Fmk 3 for a
BODIPYTMRﬂuorophore (Fig. 7).30 Chitobiose-based inhibitor
10 has been converted to activity-based PNGase probe 37 by
the introduction of a BODIPY ﬂuorophore at the 4-OH of
the non-reducing GlcNAc.38 Both peptide-based ABP 36 and
carbohydrate based ABP 37 label puriﬁed PNGase and labeling
Fig. 7 Activity-based probes for peptide N-glycanase.




























































can be completely abolished by pre-incubation with Z-VAD-Fmk.
Labeling of E. coli cell-extracts overexpressing yeast PNGase with
either probe resulted in a single band in the ﬂuorescence image.
Furthermore, ABP 37 is cell-permeable and inhibits PNGase
in vivo as was evidenced in a substrate-based assay.
Lysosomal degradation of N-linked glycoproteins:
glycosylasparaginase and its inhibitors
Mature N-linked glycoproteins are degraded in the lysosome in
a bidirectional process. The non-reducing end carbohydrates of
complex N-glycans are removed stepwise by the exo-glycosidases
present in the lysosome (Fig. 8). Classiﬁcation of glycosidases is
based on their substrate, mode of action and mechanism. These
enzymes will be further discussed in the second part of this review.
Fig. 8 Bidirectional degradation ofN-linked glycoproteins. The glycan is
degraded starting from the non-reducing (direction denoted by the arrow).
In the ﬁnal step, the glycosyl–asparagine linkage is hydrolyzed by glycosy-
lasparaginase (bold). Carbohydrates are indicated as follows: D-sialic acid
(black diamond), D-galactose (clear circle), D-N-acetylglucosamine (grey
square), D-mannose (grey circle) and L-fucose (grey triangle).
Simultaneous to the degradation of the carbohydrate part, the
protein is disassembled by proteinases such as cathepsins A, B, C,
D, H, and L.39 The ﬁnal step in the degradation is hydrolysis of
the protein–carbohydrate linkage by glycosylasparaginase (GA).
This amidase belongs to the N-terminal nucleophile hydro-
lase superfamily and is produced as zymogen. Autoproteolitic
cleavage of a distorted scissile bond in the precursor liberates
the nucleophilic N-terminal threonine residue located near the
top of the funnel-shaped active site.40 The binding-pockets for
the a-amino and a-carboxyl group of the asparagine residue are
deep in the active site of GA and binding of (N-GlcNAc)Asn
and analogues thereof to these pockets has been studied in
detail. Prerequisite for binding of substrates to GA is complete
degradation of the peptide part as was revealed by Risely et
al.41 Substrates wherein the carboxylic acid was altered were
not hydrolyzed by GA, clearly indicating the importance of
the carboxylic acid in binding. Furthermore, it was shown that
the a-amine group acts as an anchor and could be replaced
by non-polar groups with a similar size. Modiﬁcation of the
carbohydrate part is well tolerated by the funnel shaped active
site. A wide variety of asparagine analogues have been synthesized
in which the GlcNAc moiety is replaced by various moieties,
including carbohydrates (other than GlcNAc), amino acids and
methylcoumarine. All these substrate analogues are hydrolyzed by
GA. Removal of remaining a-1,6-fucose residues by fucosidases
however is essential, since these residues obstruct binding of the
substrate to GA.42 The mechanism of GA was unravelled with a
combination of crystallographic studies43 using mutated enzyme
and kinetic studies44 employing analogues of (N-GlcNAc)Asn in
which the carbohydrate part is substituted with a 4¢-substituted-
aniline. The following mechanism was established (Fig. 9). The
a-amino group of the catalytic residue acts as a base and polarizes
the nucleophilic b-hydroxyl through the side chain of a threonine
residue 170 (GA fromF.meningosepticum).Nucleophilic attack on
Fig. 9 The hydrolysis of glycosyl-asparagine by F. meningosepticum glycosyl-asparaginase.




























































the amide bond causes the formation of a tetrahedral intermediate,
which is stabilized by the oxyanion hole. Breakdown of the
tetrahedral adduct liberates N-acetyl glucosamine and forms b-
aspartic acid ester, which in kinetic studies turned out to be the
rate limiting step. Hydrolysis of the ester regenerates the active
enzyme. The only reported mechanism based inhibitor of GA
so far, 5-diazo-4-oxo-L-norvaline (38), covalently modiﬁed the
active site residue forming an ether-bond (Fig. 10).45 With the
mechanism of the enzyme known in detail however the design of
ABPs should be feasible. For instance, the mechanism of action of
the enzyme rather resembles that of another N-terminal threonine
hydrolase, the proteasome. Proteasomes in turn have been subject
to numerousABPP studies and a variety of electrophilic traps with
which proteasome active sites are efﬁciently modiﬁed are known.
These include vinyl sulfones and epoxyketones and grafting these
moieties onto GlcNAc-Asp may be an entrance to the design of
GA ABPs.
Fig. 10 Mechanism based inhibitor of glycosyl asparaginase.
Biosynthesis of O-glycoconjugates
O-glycoproteins and their structurally related lipid counterparts,
the glycolipids constitute a large and diverse class of glyco-
conjugates. Glycosyltransferases catalyze the synthesis of these
glycoconjugates by transferring the carbohydrate from a glycosyl
donor to their substrate, the acceptor.46 In mammals, two main
folds have been observed for glycosyltransferases, GT-A and GT-
B, which are both Rossmann type.47 This fold is characteristic for
nucleotide binding enzymes and it accommodates the nucleotide
diphosphate leaving group of the donor, the most common
leaving group in mammals. Examples of donors containing
this leaving group are UDP-a-Glc 39, UDP-a-Gal 40, UDP-
a-GlcNAc 41 and GDP-a-Man 42. Sialyl transferases employ
nucleotide monophosphates such as CMP-b-Neu5Ac 43 (Fig.
11). Departure of the leaving group, which is often facilitated
by a divalent cation located at the active site is followed by
the transfer of the carbohydrate. Depending on the enzyme,
glycosylation can happen either with inversion or retention of
the anomeric centre. In inverting transferases, the leaving group
is replaced in a direct SN2 like displacement. The mechanism of
retaining glycosyltransferases is less clear. A double displacement
mechanism has been proposed. First, a nucleophilic residue of
the enzyme would replace the leaving group forming a covalent
glycosyl–enzyme complex. In the second step, the acceptor reacts
with the formed adduct. Both the lack of a generally conserved
nucleophilic residue at the active site of glycosyl transferases
and the fact that no covalently linked glycosyl–enzyme complex
has been observed to date led to the postulation of a second
mechanism. In this mechanism, the leaving group is replaced in
an SN1 like fashion, with the reactive species being a short-lived
oxocarbenium ion. Recently, glycosyl transferases that use donors
containing an alternative leaving group (lipid phosphates and
unsubstituted phosphates) have been reported and some of these
enzymes do not have the typical Rossmann fold.48 The acceptor
is often a hydroxyl of another carbohydrate but it can also be a
lipid, protein, nucleic acid and a whole variety of small molecules.
In enzymes with the GT-A fold, the C-terminus is highly variable
and associated with the accommodation of the acceptor.49 Within
the GT-B fold, the N-terminus is variable and therefore believed
to be in involved with the recognition of substrate.50
Degradation of O-glycoconjugates
The glycosidic bond inO-glyconjugates is hydrolyzed by glycoside
hydrolases, also known as glycosidases.51 This large class of
enzymes comprises up to 1%of the genome. Various attempts have
beenmade to classify glycosidases. A ﬁrst classiﬁcation is based on
the substrate speciﬁcity of the enzyme. For example, b-glucosides
are the optimal b-glucosidase substrates. This speciﬁcity allows
differentiation in various classes. Although being the simplest
classiﬁcation, it has some disadvantages. Some glycosidases are
capable of hydrolyzing several substrates and, furthermore, struc-
turally unrelated enzymes can have an identical classiﬁcation. A
second classiﬁcation has been made on the mechanism of the
enzymes. Based on the stereochemical outcome of the anomeric
center of the product, there are two main mechanisms for
hydrolysis of glycosidic bonds, namely inverting and retaining.
Fig. 11 Nucleotide based glycosyl donors.




























































Fig. 12 General mechanism of glycosidases (A) inverting, (B) retaining. Alternative nucleophiles are depicted in (C) and (D).
Hydrolysis by inverting glycosidases results in inversion of the
conﬁguration of the anomeric center (for instance, a becomes b),
whereas the conﬁguration at the anomeric center is not changed
by retaining glycosidases. Koshland was the ﬁrst to recognize this
in 1953 and postulated that inversion of the anomeric center
was caused by general acid activation of the glycosidic bond
followed by SN2 substitution of the anomeric center with a water
molecule.52 He also proposed a double displacement mechanism
for the retaining glycosidases, in which ﬁrst an enzyme–glycoside
complex is formed, which is hydrolyzed in the second step. The
two postulatedmechanisms are well established today. In inverting
glycosidases, two carboxylic acid residues are located at the op-
posing sites of the active site, and are at least 6 A˚ apart. One of the
carboxylic acids is protonated. This carboxylic acid acts as an acid
catalyst to activate the glycosidic bond. The other carboxylic acid
is deprotonated and is responsible for deprotonation of the water
molecule.Hydrolysis proceeds through a single oxocarbenium ion-
like transition state. No covalent glycosyl–enzyme adducts are
formed during hydrolysis (Fig. 12A). The active site of retaining
glycosidases also contains two carboxylic acidswhich are generally
separated by~5.5 A˚. Similar to the inverting glycosidase, one of the
carboxylic residues acts as a general acid catalyst. Now, however,
the other residue does not act as base, but instead performs a
nucleophilic attack forming a covalent glycosyl–enzyme adduct.
In the next step, the formed covalent adduct is hydrolyzed via
the reversed pathway. The residue that acted as an acid in the
ﬁrst step of hydrolysis now acts as a base abstracting a proton
from the incoming water molecule (Fig. 12B). Besides carboxylic
acids, several other nucleophiles have been observed in retaining
glycosidase. The N-acetyl group adjacent to the anomeric center
of the substrate acts as the nucleophilic residue in hexosaminidases
forming an oxazoline intermediate (Fig. 12C),53 and in retaining
sialidases a tyrosine residue functions as nucleophile (Fig. 12D).54
Although the mechanism gives useful information about the
enzyme, on its own this classiﬁcation is not suitable.
Yet another classiﬁcation has been made on the mode of action
of the enzymes. Depending on the hydrolysis of polysaccharides,
glycosidases can be divided in endo- and exo-glycosidases.55
Exo-glycosidases selectively remove the terminal residues of the
reducing end of polysaccharides. In the active sites, extensive
interactions are made with the substrate enabling recognition
of a speciﬁc glycoside. Endo-glycosidases hydrolyze glycosidic
bonds within polysaccharides and have a cleft/tunnel shaped
active site. Classiﬁcation by the mode of action can be confusing
too, since many glycosidases possess intermediate activity. Finally,
in 1991 Henrissat came up with another proposal.56 In this
work, glycosidases were classiﬁed on their amino acid sequence
and predicted structural relationship. Using this strategy, the
glycosidases have been divided into 100 families, which can be
found on http://www.cazy.org. Since the structure of the enzymes
is related in these families, the mechanism of the hydrolysis of the
glycosidic bond is also conserved. In some cases, themembers from
different families share an equal mechanism and these enzymes
form a so-called glycoside hydrolase clan.
Glycosidase inhibitors and activity-based probes
The development of inhibitors and activity-based probes for
glycosidases has received considerable attention, due to their
potential therapeutic value as well as their usefulness in studies
towards the mechanism and active site residues of glycosidases.
Two types of inhibitors, namely non-covalent and covalent, have




























































Fig. 13 (A) substrate-based photoafﬁnity labels. (B) Deoxynojirimycin based photoafﬁnity labels.
been described in literature. The non-covalent inhibitors, the
largest class, have extensively been reviewed.57 Here, the focus will
be on the covalent inhibitors and their conversion to ABPs. The
use of non-covalent inhibitors as leads for ABPs will be discussed
brieﬂy.
Probes based on non-covalent inhibitors
Photoafﬁnity probes have been applied for many enzymes. Such
molecules are quite useful to label enzymes that do not form a co-
valent substrate–enzyme intermediate such as metalloproteases.58
The general structure of these probes is comparable to that of
activity-based probes. Both consist of a label/reporter group
for visualization purposes and a recognition element (in the
case of a photoprobe, a non-covalent inhibitor), which facilitates
selective and strong binding to the enzyme. In contrast to ABPs,
photoactivatable probes do not have a warhead that reacts in
a mechanism based fashion with the enzyme. Instead, they are
equipped with a photoactivatable group. After irradiation with
light of the appropriate wavelength, this group is converted into
a highly reactive intermediate, which reacts with the enzyme.
In two separate papers, Khun et al. utilized this approach to
label a galactosidase and a hexosaminidase respectively with
tritium containing photo-probes 44 and 45 (Fig. 13).59 Upon
photolysis of the diazirine in 44 and 45, a carbene is formed
which undergoes an insertion reactionwith a nearby residuewithin
the enzyme. Two active site fragments of the b-galactosidase and
one of hexosaminidase were identiﬁed by proteolysis and Edmann
degradation of the radioactive fragments of enzyme labeled with
44 or 45 respectively. For the b-galactosidase an additionally
a peptide which was located remote from the active site was
detected.60
Recently, three photoafﬁnity probes based on the broad-
spectrum glucosidase inhibitor deoxynojirimycin have been re-
ported. Alkylation of deoxynojirimycin with a linker equipped
with a p-azidosalicyl amide, as photocrosslinker, and 125I, as
radioactive label (Fig. 13) afforded a probe for glucosidase I (46).61
Radioactive labeling of a single 85 kDa protein corresponding
to the size of glucosidase I was observed when a microsomal
protein fraction was subjected to 46 and this signal could be
abolished by incubation with reversible inhibitors showing the
selectivity of 46. Van Scherpenzeel et al. used a similar approach
for the synthesis of a probe for lysosomal glucocerebrosidase and
non-lysosomal glucoceramidase.62 By alkylating deoxynojirimycin
with a benzophenone photocrosslinker and an alkyne as ligation
handle probe 47 was obtained which potently inhibits and after
irradiation with UV light and copper catalyzed click reaction with
a ﬂuorophore can be used to visualize these enzymes. Very recently,
Gandy et al. capitalized on the same idea for the synthesis of an
exo-a glucosidase probe 48.63
Quinone methide probes
In the early nineties, the search for selective glycosidase inhibitors
let to the introduction of quinone methide inhibitors.64 These
compounds are solely activated after enzymatic cleavage and
should therefore have enhanced selectivity for the targeted enzyme.
Their design was guided by the successful inhibition of proteases
and esterases with chloromethylaryl esters and amides.65 The
corresponding glycoside analogues synthesized by Halazy et al.
contain an ortho or para-diﬂuoromethylaryl group 49 as the latent
reactive group. Hydrolysis of the glycosidic bond by a glycosidases
liberates diﬂuoromethyl phenolate 50 as is shown in Fig. 14.
Fluorine rapidly eliminates forming reactive quinone methide
intermediate 51. Any nucleophile present in the active site can
perform a Michael reaction with 51 after which a covalent adduct
is formed (Fig. 14).
Although this method, together with the photoafﬁnity labeling
approach, is currently the only method that can be used to
label inverting glycosidases, it has a major disadvantage and
that is that the afﬁnity for the enzyme is lost by cleavage of the
glycosidic bond. Diffusion of the reactive quinone methide from
the active site of the enzyme leads to cross-reactivity and labeling
of the targeted enzyme at multiple sites, limiting the use quinone
methide probes. This limitation notwithstanding, the approach
has found some successful applications. In 1997, Janda and co-
workers used the (diﬂuoromethyl)aryl-b-glycosides as lead for the
design of activity-based probe 52.66 The biotin in 52 allowed
detection of antibodies showing galactosidase activity via a facile
streptavidin-based ELISA assay (Fig. 15). Ichikawa elaborated
on this paper and designed a set of probes (53–55), which were
used to label partially puriﬁed O-GlcNAcase.67 Western-blotting
showed that several proteins were tagged with biotin by 53–
55. However, afﬁnity puriﬁcation of the formed covalent adduct
proved in the case of the diﬂuorine probes 53 and 54 troublesome.
Elimination of the remaining ﬂuorine facilitates the regeneration
of a quinone methide. Attack of water on the resulting methide
is followed by conversion to the aldehyde liberating the enzyme
(lower part of Fig. 14). Release of the enzyme could be prevented
by reacting O-GlcNAcase with monoﬂuoromethyl probe 55
and a single protein was obtained after enrichment. A similar
probe (56) was synthesized for b-glucosidases by Lo and co-
workers.68 This probe, containing a ﬂuoromethyl at the para-
position, worked well on puriﬁed b-glucosidases. However, in
complex protein samples severe cross-reactivity was observed. In
later studies, various puriﬁed glycosidases such as galactosidases,
xylanases andneuroaminidases have successfully been labeledwith




























































Fig. 14 Mechanism of quinone methides.
Fig. 15 Quinone methide activity-based probes. A range of linkers was used in these probes.
quinone methide probes. Especially noteworthy are the papers of
Kurogohchi et al. and Lu et al. in which glycosidases are labeled
in biologically relevant samples.69 In these papers, probe 57 is
used to label galactosidases with a dansyl group and probe 58 is
used to biotinylate neuroaminidases on the surface membrane of
inﬂuenza.
Finally, in a very recent contribution, Withers and co-workers
developed novel histological and cell-labeling reagents that in
contrast to ﬂuorogenic substrates (which have previously been
used for this purpose) do not diffuse away from the site of
cleavage.70 Their elegant strategy capitalizes on the intrinsic
disadvantage of quinonemethide probes, namely that upon release
of the Michael acceptor, reaction with a nearby nucleophile is
slow and therefore in all likelihood the reactive group will to
a large extent diffuse from the active site. They reasoned that
althoughdiffusionwould out-compete the formationof an enzyme
adduct, the reactivity of the Michael acceptor would be sufﬁcient
enough to link the reporter to a nearby entity. In this fashion, the
reporter would at least be trapped (and accumulate) in the same
subcellular compartment as the target glycosidase. They proved
the validity of this concept by the design of a series of coumarin
glycosides 59–61 (Fig. 16) targeting glucuronidase, glucosidase
and galactosidase. Histological staining of glucuronidase with
59 in Arabidopsis plants was readily achieved whereas labeling
with methylumbelliferyl glucuronide did not show any labeling
at all. Cell-labeling experiments with E. coli cells expressing
Argobacterium sp. b-glucosidase/galactosidase and P. pastoris
expressing Thai rosewood b-glucosidase revealed that cells labeled
with 60 and 61 remained ﬂuorescent even after extensive washing
and could be sorted using ﬂuorescence assisted cell sorting.
2-Deoxy-2-ﬂuoroglycoside probes
Activated 2-deoxy-2-ﬂuoroglycosides were introduced as in-
hibitors of retaining b-glycosidases in 1987 by With-
ers and co-workers.71 The 2-ﬂuoride group destabilizes the




























































Fig. 16 Quinone methide probes that can be used for histological staining.
oxocarbenium-like transition state formed during the glycosyla-
tion and deglycosylation step. Consequently, the rate of formation
and the rate of hydrolysis of the glycosyl-enzyme adduct is
decreased. An activated anomeric leaving group increases the
glycosylation rate leading to accumulation of the glycosyl–
enzyme adduct (Fig. 17). Later it was reported that activated
5-ﬂuoroglycosides inhibit glycosidases in a similar fashion.72
Interestingly, these compounds inhibit both a- and b-glycosidases.
Lifetimes of the formed glycosyl–enzyme adducts are sufﬁcient
to allow their isolation for ensuing sequence analysis. The
application of ﬂuoroglycosides led to the identiﬁcation of the
nucleophilic residue of various enzymes, including the nucleophilic
residues of various a- and b-glycosidases,73 sialidases74 and a
glucosaminidase.75 In an interesting recent application, human
acid glucosylceramidase, the enzyme deﬁcient inGaucher patients,
was covalently and irreversibly labeled with a 18F-2-deoxy-2-
ﬂuoroglucoside and subsequently administered to animal models.
In this fashion, distribution of the enzyme can be monitored via
positron electron tomography (PET), which might be of use in
the assessment of the efﬁcacy of enzyme replacement therapy for
Gaucher patients.76
Fig. 17 Mechanism based inhibition of glycosidases with ﬂuorosugar.
In the past decade, 2-deoxy-2-ﬂuoroglycosides have served as
inspiration for the development of ABPs aimed at retaining
glycosidases. Bertozzi and Vocadlo developed an elegant strategy
to proﬁle exo-glycosidases. They realized that binding of an ABP
containing a large reporter group might be hampered by the
pocket shaped active site of exo-glycosidases, that the introduction
of a small ligation handle would be tolerated by the enzyme
and that this handle could be elaborated with a reporter group
after labeling. To this end, 2-deoxy-2-ﬂuorogalactosyl ﬂuoride
was converted into ABP 62 by incorporation of an azido group
(Fig. 18).77 Kinetics studies with E. coli b-galactosidase (LacZ)
revealed that the modiﬁcation of the C-6 position of galactosides
was tolerated and therefore the azido group was introduced at
this position. Although being time- and concentration-dependent,
inactivation by 62 was rather slow with a second-order rate
constant of 0.2 M-1 min-1. Both puriﬁed LacZ and LacZ in lysate
of E. coli induced with IPTG could be inhibited with probe 62.
Fig. 18 Exo glycosidase probes.
The formed covalent adduct was visualized by modiﬁcation of
the azido group with FLAG-tag using the Staudinger–Bertozzi
ligation followed by Western-blotting. In this fashion, not only
LacZ was labeled with 62 but six different retaining b-glycosidases
from the families 1, 2 and 35 were labeled as well, demonstrating
the versatility of this approach.
Recently, Stubbs et al. reported a probe for retaining b-
glucosaminidases based on the idea of Vocadlo and Bertozzi.78
In the X-ray structure of Vibrio cholerae NagZ (VCNagZ), they
observed a large pocket around the 2-acetamido binding site. They
envisioned that replacing the 2-acetamido-group by an azidoacetyl
wouldminimize loss in carbohydrate-enzyme interactions. Indeed,
the resulting probe 63 proved a good glucosaminidase inhibitor.
Despite the inherent instability of the O-acylal linkage (hydrolysis
of the linkage was observed during gel-electrophoresis), probe 63
was used to successfully label puriﬁed VCNagZ in combination
with FLAG-tagged phosphine. From this point of view, the assay
was remarkably sensitive and as little as 80 ng could be visualized.
Stubbs took advantage of the inherent instability to increase
the sensitivity of glucosaminidase labeling by the development
of the following procedure. Cell-lysate was reacted with probe
63 and modiﬁed with a biotin using the copper catalyzed click
reaction. The biotinylated proteins were immobilized on avidine
resin. Unlabeled proteins were washed away after which the
resin was boiled in SDS-PAGE loading buffer to hydrolyze
the acylal linkage. The liberated enzymes were resolved by gel-
electrophoresis and stained using general protein staining. A
putative glucosaminidase of P. aeruginosa was captured using this
method.
Fluoroglycoside probes have also found use in protein proﬁling
of endo-glycosidases (Fig. 19). In contrast to the above-described
exo-glycosidase, modiﬁcation of the glycoside with large tags is
well tolerated by the canyon like active site of these enzymes.
Withers and co-workers anticipated this and synthesized xylanase
probes 64 and 65 containing a biotin as reporter group.79 After
conﬁrming that compounds 64 and 65 still inhibited b-glycanases
and that they could be used as probes, Withers and co-workers
used them to study the proteome secreted by Cellulomonas
ﬁmi. These soil bacteria degrade cellulose and xylan from plant




























































Fig. 19 Endoglycosidases probes.
sources, for which they produce and secrete an array of xylanases
and cellulases. Using probe 65, a new b-glycanase activity was
discovered in the extracellular proteome of C. ﬁmi.80 The ex-
creted glycanases often show mixed substrate speciﬁcity (that is
endoxylanase/cellulase speciﬁcity). Xylanases from family 10 are
able to degrade both cellulose and xylan. The family 11 xylanases
are “true” xylanases and exclusively degrade xylan. To examine
the speciﬁcity of the secreted enzymes in greater detail, Withers
and co-workers presented a well-designed approach to distinguish
endoxylanase/cellulases from true xylanases.81 Enzymes from
family 10 and 11 were treated with two ﬂuorescent probes, a
2-deoxy-2-ﬂuoro-b-xylobioside condensed to a red ﬂuorophore
(66) and a 2-deoxy-2-ﬂuoro-b-cellobioside conjugated to a green
ﬂuorophore (67). As anticipated, xylanases from family 10 could
be labeled with either of the probes and xylanases from family
11 could only be labeled by 66. This difference in selectivity was
exploited to investigate the inﬂuence of extracellular surroundings
on the proteome secreted by bacteria C. ﬁmi. Whereas induction
with xylan led to secretion of amixture of endoxylanase/cellulases
and some speciﬁc xylanases, induction with cellulose led to
secretion of enzymes with a mixed speciﬁcity and one speciﬁc
cellulase. Isotope-coded afﬁnity tagging (ICAT) analogues 68–71
were published as tools to quantify the labeled proteins by mass
spectrometry.82
Cyclitol epoxides and exocyclic epoxides
Conduritol B epoxide (CBE) or DL-1,2-anhydro-myo-inositol
(72) is a potent irreversible inhibitor of b-glucosidases (Fig.
20). After its discovery in 1966 by Legler,83 it has been used to
study b-glucosidases of many sources such as Aspergillus, yeast,
sweet almonds and mammals.84 Interaction of the hydroxyls in
72 with the substrate-binding pockets of the enzyme ensures
speciﬁc binding of the inhibitor to glucosidases. Activation of
the epoxide by a carboxylic acid in the active site is required
for inhibition. Upon trans-diaxial opening of the epoxide by
the nucleophilic residue, a stable ester bond is formed (Fig.
20A). This mechanism was conﬁrmed with 14C-labeled CBE.85
Cleavage of the covalent adduct by reacting it with hydroxylamine
and isolation of the released radioactive compound exclusively
afforded 1-D-chiro-inositol, which is formed by diaxial opening
of D-1,2-anhydro-myo-inositol. It was therefore reasoned that
only the D-isomer of CBE reacts with glucosidases. This makes
sense since it resembles the natural substrate, D-glucose. A
later study employing chirally pure L-1,2-anhydro-myo-inositol
showed that the L-isomer was indeed inactive to b-glucosidases.86
Interestingly, Quaroni et al. found that CBE also inhibits the
sucrase-isomaltase complex, an a-glucosidase.87 Binding to
a-glucosidases can be explained by the C-2 symmetry axis in
CBE (Fig. 20B). This axis allows the molecule to orient itself
in the active site such that the epoxide is activated and opened
trans-equatorially by the nucleophilic residue, albeit with reduced
reaction rates.88 Later it was shown that other a-glucosidases
of various sources could be inhibited by CBE, including yeast
a-glucosidase, human lysosomal a-glucosidase and plant a-
glucosidases.89 The scope of glycosidases that could be inhibited
was broadened by the synthesis of L-1,2-anhydro-myo-inositol
(the L-isomer of CBE), conduritol F epoxide 73, conduritol C
cis-epoxide 74 and trans-epoxide 75 (Fig. 20C). These analogues
of CBE inactivate yeast b-fructosidase, b-mannosidases,




























































Fig. 20 Mechanism of inhibition by CBE (A) of b-glucosidases, (B) a-glucosidases. (C) Structures of conduritol B epoxide and its analogues, (D)
structure of cyclophellitol and its analogues.
b-galactosidases, a-galactosidases and a a-fucosidase
respectively.90 Radiolabeled versions of 72–75 have been
used to determine the active site residues of a-and b-glycosidases.
An analogue of conduritol B epoxide containing an exocyclic
methylene, cyclophellitol 76, was isolated from the mushroom
strain Phellinus sp. (Fig. 20D).91 Prior to its discovery this
analogue had already been proposed as a more speciﬁc and
potent inhibitor of retaining b-glucosidases. The idea was that
the introduction of a methylene would not only increase the
binding-afﬁnity but also break the symmetry of the molecule and
thereby prevent binding to a-glucosidases. Indeed this proved
the case, and cyclophellitol 76 potently inhibits b-glucosidases
(inhibition of almond b-glucosidase is 92 fold more effective
than CBE)92 and leaves other glycosidases practically untouched
(partial inhibition of b-xylosidase and a-glucosidase activities
has been observed).93 Soon after the discovery of cyclophellitol,
unnatural diastereomers with the a-gluco 77, b-manno 78 and
a-manno 79 conﬁguration were synthesized and it was shown
that these compounds inhibit the corresponding a-glucosidases,
b-mannosidases and a-mannosidases.94
Exocyclic epoxides 80—85 (Fig. 21) have also been explored
as glycosidase inhibitors. In general these compounds consist of
a carbohydrate tailored at the reducing end with an epoxy-alkyl
chain. A diminished activity was observed for exo-glycosidases
compared to CBE,95 but these compounds proved to be excellent
inhibitors of endo-glycosidases.96 By changing the spacer length
and stereochemistry of the warhead of these compounds, speci-
ﬁcity for a certain enzyme could be generated.97
Fig. 21 Exocyclic epoxides.
Of the epoxide based inhibitors, conduritol B epoxide especially,
and to a lesser extent cyclophellitol, have found application in
glycobiology studies. Both compounds selectively inhibit human
acid b-glucosidase, also known as glucocerebrosidase or GBA-
1, in mammals and have therefore been widely applied in the
study towards Gaucher disease. Glucocerebrosidase is deﬁcient
in Gaucher patients resulting in accumulation of its substrate,
glucosylceramide. By treating cells and mice with 72 and 76 a
phenotype resembling Gaucher disease could be induced.98 The
selectivity of CBEwas also exploited for the discovery of unknown
mammalian b-glucosidases. Selective inhibition of glucocerebrosi-
dase by CBE or cyclophellitol followed by identiﬁcation of the
enzymes responsible for the residual activity led to the discovery
of acid b-glucosidase 2 (GBA-2) and the broad speciﬁcity b-
glucosidase (GBA-3).99 Recently, the crystal structure of CBE
covalently bound to glucocerebrosidase was published.100
Although widely applied as inhibitors to study glycosidase
activities, CBE and cyclophellitol were only recognized as leads
for the development of glycosidase ABPs. This is rather surprising
given that theirmode of action towards retaining beta-glucosidase,
which involves the formation of a covalent adduct, invites the
design of ABPs by grafting a reporter group onto the cyclitol
core. As outlined above, this strategy has met with considerable
success starting from 2-deoxy-2-ﬂuoroglycosides and the available
literature point towards cyclitol epoxides as the superior inhibitor
of the two classes.We therefore turned our attention to this, and in
a ﬁrst study compared the efﬁcacy of both classes of compounds
in inactivating two retaining beta-glucosidases, namely human
acid glucosylceramidase (GBA) and almond beta-glucosidase
(ABG).101 In our studies we included an evaluation of the merits
of direct labeling (grafting a BODIPY ﬂuorophore onto the ABP
core) and two-step bioorthogonal labeling (in which case an azide
was installed as the ligation handle). This led to the design of the
panel of glycosidase ABPs 86–94 (Fig. 22). As expected, we found
that the cyclophellitol derivatives (91–94) vastly outperform their
2-deoxy-2-ﬂuoro counterparts (86–90) in inhibiting both enzymes.
A rather more unexpected ﬁnding is that cyclophellitol probes 93
and 94, with the BODIPY installed at C6, proved to be the most
effective GBA ABP of the series. Apparently, and as opposed




























































Fig. 22 Epoxide based glucosidase probes and their corresponding ﬂuoroglycoside probes.
to ABG, GBA is not averse, and in fact welcomes the presence
of a large hydrophobic group at this position, making the probe
both very sensitive and highly speciﬁc (labeling of tissue from
various origin gave only a single band, corresponding to the –
low abundance – protein, GBA). We capitalized on this ﬁnding
by monitoring in situ in tissue and animal models the activity
of GBA in the context of Gaucher disease and found, amongst
other results, that mutated GBA can be rescued to some extent by
administering isofagomine as a chemical chaperone.102 The ability
to monitor GBA activity inside cells, thanks to the ABP probe,
sheds new light on such active site directed chemical chaperones
and we found that the efﬁcacy of isofagomine is quite a bit lower
when looking in the appropriate environment than what is alluded
to in the literature. Returning to the bioorthogonal chemistry, we
found that detecting glycosidase activities in cell extracts through
click chemistry using azide probe 91 proved cumbersome. Here
optimization of the ligation protocols, or indeed the development
of new strategies is needed.103
Alternative degradation pathways
For the degradation of glycoproteins, alternative pathways have
been described such as excretion and autophagy of the ER.104
Moreover, ABP-like studies revealed that the protein part of
these glycoconjugates can be degraded prior to hydrolysis of the
glycosidic bonds. Until recently, it was generally believed that
deglycosylation of glycoproteinswas required prior to degradation
by the proteasome. It was reasoned that the steric bulk opposed by
the glycan would prevent entry of the glycoprotein to the catalytic
core of the proteasome and that it as such prevents breakdown
of the glycoprotein. Interestingly, Ploegh et al. observed that
inhibition of PNGase with Z-VAD-Fmk did not inhibit protea-
somal degradation of N-linked glycoproteins. Ito and co-workers
used ﬂuorescent glycopeptides 95–98 to unambiguously establish
that N-linked glycoproteins could be degraded by proteasome
(Fig. 23).105 Peptides 95–98 consist of a proteasomal recognition
element, Z-Leu–Leu–Leu, a N-glycosylation sequence, Asn–
Gly–Thr, and rhodamine as a ﬂuorescent tag. Cleavage of the
proteasomal recognition element could be monitored by HPLC.
Hydrolysis of the peptide bond results in the formation of a novel
ﬂuorescent glycopeptide. Quantiﬁcation of the ﬂuorescence of the
Fig. 23 Fluorescent glycosylated proteasome substrates.
newly formed peptide revealed that the proteasome is capable
of degrading N-linked glycopeptides, although with decreased
effectiveness. These results were corroborated by Navon and co-
workers.106 Glycosylated proteins containing one or multiple N-
linked glycans were completely degraded by the proteasome. The
global degradation pattern was not changed by N-linked glycans.
They did however have a local effect. Reduced expression of epi-
topes near a glycosylation site was observed in in vivo experiments.
Analysis of the degradation products in vitro supported these
results. N-terminally extended peptides were observed near N-
linked glycans.
Next to the degradation of N-linked glycoproteins also the
degradation of O-linked glycoproteins by the proteasome has
been studied. Protein O-GlcNAcylation is another major post-
translational modiﬁcation in the nucleus and cytosol and it
was therefore reasoned that the proteasome will encounter O-
GlcNAcylated substrates.107 We used an ABP-based strategy to
study whether the proteasome can handle such substrates.108
The selective proteasome inhibitor epoxomicin was N-terminally
elongated with O-GlcNAc-Ser derivative and equipped with
an azidoacetyl group which could be modiﬁed with biotin for
visualization purposes (probes 99–102, Fig. 24). Incorporating
the azidoacetyl group either at N-terminus of peptide (99 and
100) or at GlcNAc residue (101 and 102) allowed monitoring
deglycosylation of probe by comparing the labeling signal of the
probes (Deglycosylation of probes 101 and 102 leads to removal of
the azido group whereas it will leave the azido group untouched in
probes 99 and 100). In a competition experiment,109 these probes
not only blocked labeling, but they did so with only slightly di-
minished potency compared to the parent compound epoxomicin.




























































Fig. 24 O-GlcNAcylated proteasome probes.
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The covalent adduct could be visualized by Staudinger–Bertozzi
modiﬁcation, clearly demonstrating that deglycosylation prior to
proteasome binding is not a prerequisite. Furthermore, there is
not a signiﬁcant difference in the labeling pattern which indicates
that the probes are not subject to deglycosylation. It is therefore
valid to ascertain that O-GlcNAcylated proteins are degraded by
the proteasome.
Concluding remarks
Activity-based proﬁling of glycoconjugate processing enzymes has
come a long way in the past decade and ABPs have been used to
study both the glycoconjugation enzymes and glycoconjugate pro-
cessing.Although generally considered difﬁcult to target,ABPs for
various enzymes involved in degradation of glyconjugates have
been reported and with the current knowledge of the mechanisms
of the enzymes it should be possible to design probes for most of
the untargeted enzymes, such as glucosylasparaginase (Table 1).
Despite this, it is clear that there are still issues that should be
addressed to obtain successful labeling. All reported probes so far
have their advantages but also disadvantages.Major disadvantages
of PNGase probes may be their selectivity and by combining
peptidic and glycosidic structural elements in a single probe this
issue may be addressed. For glycosidase ABPs, several problems
need to be addressed. First of all, inverting glycosidases do not
form a covalent intermediate and can therefore only be labeled
with photoafﬁnity probes and quinone methide probes, but their
use is some what limited due to their moderate selectivity. Another
problem in the development of glycosidase probes is the exquisite
selectivity of exo-glycosidases. Incorporation of a reporter group
decreases in most cases the activity and the selectivity and
sensitivity of two-step labeling strategies currently employed is
not sufﬁcient. Optimization of the two-step labeling or alternative
strategies (such as the incorporation of the reporter group at the
aglycone site) are required to obtain broad spectrum probes for
this class of enzymes. When these issues are addressed, new tools
for glycoconjugate processing enzymes will be useful both for
fundamental studies as well as diagnostics.
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